3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides

US11591311B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Ilona GUTCHER · Berlin, DE
• Ulrike Röhn · Berlin, DE
• Ludwig Zorn · Berlin, DE
• Lars Röse · Berlin, DE
• Benjamin Bader · Berlin, DE
• Christina KOBER · Lollar, DE
• Rafael CARRETERO · Heidelberg, DE
• Detlef Stöckigt · Potsdam, DE
• Michael Platten · Heidelberg, DE

Key dates

• Filing date: Nov 16, 2018
• Grant date: Feb 28, 2023
• Expiry date: Nov 16, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyri-dazine-4-carboxamide compounds of general formula (I): in which R1, R2, R4, R5, R6, X, Y and Z are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.